November 7, 2016
“We appreciated our interaction with the DMC and are pleased that they have recommended the ACCUTE study continue as designed,” said Dr. Wayne Dankner, Chief Medical Officer of Atox Bio.  “A treatment is needed for this devastating condition and we are hopeful that AB103 will be the first product specifically approved for NSTI. We are...


New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020
A female dog may well be the answer
24. January 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge